100% Original Factory Sglt2 Inhibitor Canagliflozin - Dabigatran Etexilate Mesylate – CPF

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

We have been ready to share our knowledge of internet marketing worldwide and recommend you suitable merchandise at most aggressive rates. So Profi Tools present you very best price of money and we are ready to develop alongside one another with Ticagrelor 90 Mg Uses, Stopping Ticagrelor After 12 Months, Sofosbuvir Manufacturer, We always concertrating on developing new creative product to meet request from our clients all over the world. Join us and let's make driving safer and funnier together!
100% Original Factory Sglt2 Inhibitor Canagliflozin - Dabigatran Etexilate Mesylate – CPF Detail:

Description

Dabigatran etexilate mesylate (BIBR 1048MS) is an orally active prodrug of Dabigatran. Dabigatran etexilate mesylate has anticoagulant effects and is used for the prophylaxis of venousthromboembolism and stroke due to atrial fibrillation.

Background

Description: IC50 Value: 4.5nM (Ki); 10nM(Thrombin-induced platelet aggregation) [1] Dabigatran is a reversible and selective, direct thrombin inhibitor (DTI) undergoing advanced clinical development as its orally active prodrug,dabigatran etexilate. in vitro: Dabigatran selectively and reversibly inhibited human thrombin(Ki: 4.5 nM) as well as thrombin-induced platelet aggregation (IC(50): 10 nM), while showing no inhibitory effect on other platelet-stimulating agents.Thrombin generation in platelet-poor plasma (PPP), measured as the endogenous thrombin potential (ETP) was inhibited concentration-dependently (IC(50): 0.56 microM). Dabigatran demonstrated concentration-dependent anticoagulant effects in various species in vitro, doubling the activated partial thromboplastin time (aPTT), prothrombin time (PT) and ecarin clotting time (ECT) in human PPP at concentrations of 0.23, 0.83 and 0.18 microM, respectively [1]. in vivo: Dabigatran prolonged the aPTT dose-dependently after intravenous administration in rats (0.3, 1 and 3 mg/kg) and rhesus monkeys (0.15, 0.3 and 0.6 mg/kg). Dose- and time-dependent anticoagulant effects were observed with dabigatran etexilate administered orally to conscious rats (10, 20 and 50 mg/kg) or rhesus monkeys (1, 2.5 or 5 mg/kg), with maximum effects observed between 30 and 120 min after administration, respectively [1]. Patients treated with dabigatran etexilate experienced fewer ischaemic strokes (3.74 dabigatran etexilate vs 3.97 warfarin) and fewer combined intracranial haemorrhages and haemorrhagic strokes (0.43 dabigatran etexilate vs 0.99 warfarin) per 100 patient-years [2]. Clinical trial: An Evaluation of the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate in Hemodialysis Patients . Phase1

Storage

Powder

-20°C

3 years
 

4°C

2 years
In solvent

-80°C

6 months
 

-20°C

1 month

Clinical Trial

NCT Number Sponsor Condition Start Date

Phase

NCT02170792 Boehringer Ingelheim Healthy February 2001

Phase 1

NCT02170974 Boehringer Ingelheim Healthy July 2004

Phase 1

NCT02170831 Boehringer Ingelheim Healthy May 1999

Phase 1

NCT02170805 Boehringer Ingelheim Healthy April 2001

Phase 1

NCT02170610 Boehringer Ingelheim Healthy March 2002

Phase 1

NCT02170909 Boehringer Ingelheim Healthy December 2004

Phase 1

NCT02171000 Boehringer Ingelheim Healthy April 2005

Phase 1

NCT02170844 Boehringer Ingelheim Healthy June 2004

Phase 1

NCT02170584 Boehringer Ingelheim Healthy January 2001

Phase 1

NCT02170935 Boehringer Ingelheim Venous Thromboembolism April 2002

Phase 2

NCT02170636 Boehringer Ingelheim Healthy January 2002

Phase 1

NCT02170766 Boehringer Ingelheim Healthy October 2000

Phase 1

NCT02171442 Boehringer Ingelheim Healthy April 2002

Phase 1

NCT02170896 Boehringer Ingelheim Healthy October 2001

Phase 1

NCT02173730 Boehringer Ingelheim Healthy November 2002

Phase 1

NCT02170623 Boehringer Ingelheim Healthy February 2002

Phase 1

NCT02170116 Boehringer Ingelheim Healthy November 1998

Phase 1

NCT02170597 Boehringer Ingelheim Healthy August 2003

Phase 1

NCT01225822 Boehringer Ingelheim Venous Thromboembolism November 2002

Phase 2

NCT02170701 Boehringer Ingelheim Venous Thromboembolism October 2000

Phase 2

NCT02170740 Boehringer Ingelheim Healthy November 1999

Phase 1

NCT02170922 Boehringer Ingelheim Healthy July 1999

Phase 1

Chemical structure

Dabigatran Etexilate Mesylate

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

OUR STRENGTH

Quality management1

Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.

Quality management2

Advanced international quality management system has laid solid foundation for sales.

Quality management3

Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect. 

Quality management4

Professional Regulatory Affairs team supports the quality demands during the application and registration.


VIEW MORE


VIEW MORE

International cooperation
International cooperation
Domestic cooperation
Domestic cooperation


Product detail pictures:

100% Original Factory Sglt2 Inhibitor Canagliflozin - Dabigatran Etexilate Mesylate  – CPF detail pictures


Related Product Guide:

We are going to dedicate ourselves to providing our esteemed buyers together with the most enthusiastically thoughtful products and services for 100% Original Factory Sglt2 Inhibitor Canagliflozin - Dabigatran Etexilate Mesylate – CPF , The product will supply to all over the world, such as: Tunisia, kazan, Mali, Based on our guiding principle of quality is the key to development, we continually strive to exceed our customers' expectations. As such, we sincerely invite all interested companies to contact us for future cooperation, We welcome old and new customers to hold hands together for exploring and developing; For more information, be sure to feel free to contact us. Thanks. Advanced equipment, strict quality control, customer-orientation service, initiative summary and improvement of defects and extensive industry experience enable us to guarantee more customer satisfaction and reputation which, in return, brings us more orders and benefits. If you are interested in any of our merchandise, make sure you feel free to contact us. Inquiry or visit to our company are warmly welcome. We sincerely hope to start a win-win and friendly partnership with you. You can see more details in our website.
  • The customer service reprersentative explained very detailed, service attitude is very good, reply is very timely and comprehensive, a happy communication! We hope to have a opportunity to cooperate.
    5 Stars By Brook from Malta - 2017.09.29 11:19
    The sales manager is very patient, we communicated about three days before we decided to cooperate, finally, we are very satisfied with this cooperation!
    5 Stars By Leona from India - 2018.12.10 19:03
    Write your message here and send it to us